Arvinas, Inc. (ARVN) News
Filter ARVN News Items
ARVN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ARVN News Highlights
- For ARVN, its 30 day story count is now at 2.
- Over the past 28 days, the trend for ARVN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CONN and PFE are the most mentioned tickers in articles about ARVN.
Latest ARVN News From Around the Web
Below are the latest news stories about ARVINAS INC that investors may wish to consider to help them evaluate ARVN as an investment opportunity.
Arvinas to Participate in Upcoming Investor ConferencesNEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences: Jefferies Healthcare Conference on Thursday, June 8. A live audio webcast of the fireside chat at 11 a.m. ET will be available here and on the Events + Presentations section of the Company’s website.Goldman Sachs 44th Annua |
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual CongressNEW HAVEN, Conn. and NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) protein degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or m |
New Forecasts: Here's What Analysts Think The Future Holds For Arvinas, Inc. (NASDAQ:ARVN)Celebrations may be in order for Arvinas, Inc. ( NASDAQ:ARVN ) shareholders, with the analysts delivering a significant... |
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue EstimatesArvinas, Inc. (ARVN) delivered earnings and revenue surprises of -5.48% and 5.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update–Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests potential clinical benefit in a heavily pretreated patient population – NEW HAVEN, Conn., May 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the firs |
Arvinas to Present at the Bank of America Securities 2023 Healthcare ConferenceNEW HAVEN, Conn., May 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Randy Teel, Ph.D., Senior Vice President, Corporate and Business Development, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Tuesday, May 9 at 6:40 p.m. ET/3:40 p.m. PT in Las Vegas. A live audi |
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical TrialArvinas, Inc. (Nasdaq: ARVN) and Quantum Leap Healthcare Collaborative™ today announced that Arvinas' vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap. This study targets patients with newly diagnosed ER positive invasive cancer. Vepdegestrant is in Phase 3 clinical development for the treatment of patients with locally advanced or metastati |
Arvinas to Present at Stifel Targeted Oncology DayNEW HAVEN, Conn., April 21, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside at the Stifel Targeted Oncology Day on Wednesday, April 26 at 11:30 a.m. ET. A live audio webcast of the fireside chat will be available here and on the Events & Present |
Arvinas, Inc. (NASDAQ:ARVN) Investors Are Less Pessimistic Than ExpectedWith a price-to-sales (or "P/S") ratio of 10.9x Arvinas, Inc. ( NASDAQ:ARVN ) may be sending very bearish signals at... |
Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains?Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |